+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07778498

First-in-Human Study of TJ102 Antibody-Drug Conjugate for Advanced or Metastatic Ovarian Cancer and Solid Tumors Evaluating Safety and Preliminary Efficacy

Led by Phrontline Biopharma · Updated on 2026-10-21

150

Participants Needed

9

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating TJ102, an investigational antibody-drug conjugate ADC, to determine its safety, tolerability, and preliminary effectiveness in adults with advanced or metastatic ovarian cancer or other solid tumors who have exhausted standard treatments. The study aims to find the maximum tolerated dose MTD and the recommended dose for further testing in this patient population. Participants will receive intravenous infusions of TJ102 every three weeks. During the initial dose escalation phase, doses will increase to find the optimal level, followed by a dose expansion phase at the selected dose. The study involves regular tumor imaging to monitor response, blood sampling for drug levels and biomarker analysis, and close monitoring for side effects throughout treatment. Participants will undergo assessments including imaging scans and laboratory tests before and during treatment. Researchers will track adverse events, treatment tolerability, and various pharmacokinetic measurements such as drug concentration and half-life over up to two years. The study also measures anti-drug antibody presence and overall survival outcomes. Total participation may last several years as safety and efficacy are evaluated.

CONDITIONS

Brief Title

A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

Research Team

P

Project Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here